1ISG-001 Use of a government digital tool in drug evaluation for hospital pharmacies

<h3>Background and Importance</h3> The National Pharmacy and Medicine Institute implemented in 2015 a Digital Assessment Decision Support Tool (SiNATS) to maximise health gains and sustainability, monitor drug use and its equitable access, based in a pharmacotherapeutic/economic evaluation leading to a Public Financing Report (RAFP) that grants Early Access to Medicines (PAP). <h3>Aim and Objectives</h3> To characterise drug requests (DR) evaluated by SiNATS in hospital setting. <h3>Material and Methods</h3> A 2-year retrospective study was conducted from 2022 to 2023 in an 800-bed hospital. Clinical, pharmaceutical and economic data were submitted in SiNATS digital platform for evaluation, after local drug and therapeutics committee approval, except those from the oncology department. Data were analysed in an Excel 5.0 database. <h3>Results</h3> We enrolled 72 DR, three for stock and 69 per patient of which 75% were female and with an average age of 51 years, prescribed mainly by Internal Medicine (38%), Pneumology (21%) and Gastroenterology (11%) departments. The main DR and those with a higher approval rate are mentioned in the following table: Overall, approval rate was 75%. Rejections were mainly due to lack of compliance to PAP requirements (61%) namely existing alternative first-line options (upadacitinib and mepolizumab) and RAFP already approved (33%) (belimumab and nintedanib). Global economic budget was 969.652€ per year, of which, 667.238€ corresponding to approvals and 302.614€ to rejections. <h3>Conclusion and Relevance</h3> Our data shows a high percentage of approvals. However, upadacitinib for Crohn’s disease and mepolizumab for eosinophilic granulomatosis with polyangiitis showed higher rates of rejection, due to the existence of alternative first-line treatment options. Economic impact was high, showing the importance of the definition of utilisation criteria on a national level, by experts in the field, so that clinicians and pharmacists, as a team, can optimise treatment outcomes, in accordance with RAFP and international guidelines, while ensuring sustainability of public resources and enabling more patients to benefit from innovative therapies. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest